The UK sector is being shaped by record innovation cluster activity, major government investment programmes, strong biotech financing recovery, and shifting commercial and regulatory dynamics.

However, the recent Labour Party instability is creating hesitation, slowing some investment decisions, and raising questions about planning, tax, and regulatory continuity - all of which matter enormously to UK life sciences real estate.

Developers and institutional investors rely on predictable planning, tax, and research and development (R&D) incentives. The turmoil has created uncertainty around:

  • Planning reform timelines - delays or reversals affect major schemes in Cambridge, Oxford, and London

  • Business rates and R&D tax credits - investors want clarity before committing to long term lab developments

  • Green belt and infrastructure policy - crucial for Cambridge/Oxford expansion

Some investors seem to be pausing or slowing decisions on large speculative lab builds until the policy direction stabilises.

International investors (US pension funds, Middle Eastern sovereign wealth, Canadian REITs) are major players in UK science real estate and are sensitive to; tax stability, regulatory predictability and long term cluster strategy. The recent Labour instability has also led to:

  • Slower due diligence cycles

  • More questions about long term cluster support

  • A preference for Cambridge/Oxford over London due to stronger fundamentals

  • Capital is still available - but more selective and slower to deploy.

What seems to be emerging is that biotechs and techbio tenant companies are reacting to the political environment too; some are delaying expansion decisions, others are negotiating shorter leases or more flexible lab space, and a few seem to be exploring EU alternatives (Amsterdam, Basel, Dublin) as a hedge. Demand remains strong, but decision cycles are lengthening.

Market activity and growth drivers

It seems likely we will see the following trends across the next couple of years:

  • Techbio growth - AI native drug discovery companies such as Isomorphic Labs, Exscientia, Relation Therapeutics need dry labs, wet labs and compute in the same building

  • Biomanufacturing expansion - demand for GMP suites, pilot plants, and viral vector manufacturing rising faster than supply

  • Government incentives

The UK Life Sciences Vision and Sector Plan are pushing for:

  • Faster planning

  • More manufacturing capacity

  • Regional cluster development

Potential future trends and what’s next

Hybrid R&D space is fast becoming the norm. Buildings may well be designed for 50 - 70% lab and 30 - 50% computational space. Regional clusters are also rising as Manchester, Stevenage, Birmingham, and Edinburgh attract manufacturing and cell therapy companies. We are also seeing more pre lets and fewer speculative builds with developers becoming cautious; tenants with strong funding are getting priority.

Overall, the outlook is still being promoted in a positive manner for the sector. There remains a political drive to achieve the recent 10-year Industrial Strategy, but more still needs to be done around the NHS funding rules (VPAS) and allowing the UK to become an attractive place to invest.

Following successful practical completion in February this year, the Trinity-Oxford project, delivered by Breakthrough Properties, has been awarded Best New Building at the Life Sciences, Tech & Research Clusters Awards. Gleeds was proud to act as cost manager on this outstanding scheme. Congratulations to the individuals involved and the wider professional team: Niazi Roden, KJ Tait, Thornton Tomasetti and McLaughlin and Harvey. The project is a testament to excellent design, collaboration and high-quality execution by all parties.